Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted electric pulse treatment spare prostate cancer patients from radical surgery?

NCT ID NCT05513443

Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a focal treatment called irreversible electroporation (IRE) can control localized prostate cancer as effectively as radical treatments, but with fewer side effects. IRE uses high-voltage electrical pulses to destroy tumor cells while sparing surrounding healthy tissue. The study includes men with MRI-visible, unifocal prostate cancer who are eligible for radical treatment. The main goals are to compare urinary continence and irritative urinary symptoms between the two approaches, with secondary focus on erectile function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Irreversible electroporation (IRE), a procedure using high-voltage electrical pulses to destroy tumor cells
What this could lead to
If successful, this could offer a less invasive treatment option for localized prostate cancer that controls the tumor while preserving urinary and sexual function.
What could go wrong
The trial is relatively small and early-stage, and IRE may not control the cancer as effectively as radical treatments. There are also risks of side effects from the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 184 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age at inclusion ≥ 40 years * MRI-visible lesion * EPE 3\* \<1.5 cubic cm3 lesion volume * Gleason score 3 + 4 or 4 + 3 from a single MRI-visible lesion without any Gleason grade 4 in systematic biopsies outside of the target * PSA level ≤ 20 ng/ml * Clinical stage ≤ T2c disease * Unifocal significant disease * Life expectancy of ≥ 10 years * Sufficient proficiency in the Swedish language to understand written and verbal information about the trial, its consent process and the study questionnaires * Extraprostatic extension; 5-grade Likert scale 1= Exclusion Criteria: * Intraductal tumour * History of treatment for prostate cancer; surgery, radiation, chemotherapy or hormonal treatment * History of cardiac arrythmias * Pacemaker * Renal insufficiency; GFR\<30 * Severe illnesses such as concomitant cancers, severe cardio-vascular disease or dementia * Contraindications for magnetic resonance imaging (MRI) e.g. magnetic cerebral clips, cochlear implants or severe claustrophobia * History of bladder cancer * History of previous pelvic radiotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Karolinska Institutet

    Stockholm, Solna, 17177, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.